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Abstract
To assess the potential use of hyaluronic acid (HA) as adjuvant
therapy in rheumatoid arthritis, the anti-inflammatory and
chondroprotective effects of HA were analysed in experimental
rat antigen-induced arthritis (AIA). Lewis rats with AIA were
subjected to short-term (days 1 and 8, n = 10) or long-term
(days 1, 8, 15 and 22, n = 10) intra-articular treatment with
microbially manufactured, high-molecular-weight HA (molecular
weight, 1.7 × 106 Da; 0.5 mg/dose). In both tests, 10 buffer-
treated AIA rats served as arthritic controls and six healthy
animals served as normal controls. Arthritis was monitored by
weekly assessment of joint swelling and histological evaluation
in the short-term test (day 8) and in the long-term test (day 29).
Safranin O staining was employed to detect proteoglycan loss
from the epiphyseal growth plate and the articular cartilage of
the arthritic knee joint. Serum levels of IL-6, tumour necrosis
factor alpha and glycosaminoglycans were measured by ELISA/
kit systems (days 8 and 29). HA treatment did not significantly
influence AIA in the short-term test (days 1 and 8) but did
suppress early chronic AIA (day 15, P < 0.05); however, HA
treatment tended to aggravate chronic AIA in the long-term test
(day 29). HA completely prevented proteoglycan loss from the
epiphyseal growth plate and articular cartilage on day 8, but
induced proteoglycan loss from the epiphyseal growth plate on
day 29. Similarly, HA inhibited the histological signs of acute
inflammation and cartilage damage in the short-term test, but
augmented acute and chronic inflammation as well as cartilage
damage in the long-term test. Serum levels of IL-6, tumour
necrosis factor alpha, and glycosaminoglycans were not
influenced by HA. Local therapeutic effects of HA in AIA are
clearly biphasic, with inhibition of inflammation and cartilage
damage in the early chronic phase but with promotion of joint
swelling, inflammation and cartilage damage in the late chronic
phase.
Introduction
Rheumatoid arthritis (RA), a chronic systemic disease primarily
affecting the joints, is characterised by progressive destruc-
tion of cartilage and bony structures of the joints [1,2]. Its
social impact results from the personal suffering of patients as
well as from medical and indirect costs [3].
AIA = antigen-induced arthritis; ELISA = enzyme-linked immunosorbent assay; GAG = glycosaminoglycan; HA = hyaluronic acid; HL = HA-treated 
AIA rats, long-term test; HS = HA-treated AIA rats, short-term test; IL = interleukin; mBSA = methylated bovine serum albumin; PBS = phosphate-
buffered saline; RA = rheumatoid arthritis; TNF-α  = tumour necrosis factor alpha; UL = untreated AIA rats, long-term test; US = untreated AIA rats, 
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Hyaluronic acid (HA) is a large linear glycosaminoglycan com-
posed of repeating disaccharide units of glucuronic acid and
N-acetylglucosamine, linked via the 1–4 position of the sugar
rings [4]. The synovial fluid in the joint consists of ultrafiltrated
plasma and HA, the latter being produced by type-B synovio-
cytes of the lining layer [5]. Inflammatory changes lead to
depolymerisation of HA, resulting in a decrease of its molecu-
lar weight and its concentration [6]. Its lubricant properties
decrease, contributing to the destruction of cartilage and bone
[7].
HA protects cells and anatomical structures against mechani-
cal overloading due to its viscoelastic characteristics [8]. The
viscosity of the synovial fluid is reduced in patients with RA [9],
a deficit that can be balanced by the supply of exogenous HA
[10]. In addition, the production of endogenous synovial HA is
stimulated via the supply of exogenous HA [11].
RA is characterised by a loss of proteoglycans in the affected
joints [12,13]. HA possesses chondroprotective effects
[10,14] and is reported to inhibit the loss of proteoglycans
from the matrix of joint cartilage [15,16]. HA also blocks the
loss of proteoglycans caused by the addition of catalytic
cytokines to cultivated cartilage [17,18] and suppresses the
degradation of cartilage matrix mediated by fibronectin frag-
ments [19,20]. HA is also reported to protect the cartilage
against proteoglycan loss, against chondrocyte cell death
caused by free oxygen radicals, IL-1, or mononuclear-cell-
enriched medium, and against other alterations [14,15,21-24].
Cartilage degradation induced by neutrophil leukocytes is also
reduced by HA in vitro [25]. Injection of exogenous HA
induces a decrease of inflammatory and proliferative proc-
esses within the synovium [26]. Also, HA inhibits the prolifera-
tion [27] and migration of white blood cells [28], and affects
their adherence, chemotaxis, and phagocytosis properties
[11,29,30]. Degradation of HA by reactive oxygen species, on
the other hand, may reduce the protective properties of HA
[14,31].
In spite of the known potential benefits of HA on a number of
pathological features of RA, a general estimate of its validity for
the treatment of RA is still lacking, particularly in terms of
experimental studies in animal models of arthritis. The present
study was therefore designed to examine the effects of HA in
rat antigen-induced arthritis (AIA). This experimental monoar-
ticular arthritis shares some characteristics of RA; for example,
hyperplasia of the synovial membrane, inflammatory infiltration
of the joints, and destruction of cartilage [32]. This model is
also useful to characterise treatment responses; for example,
the reduction of inflammation or changes in the synovial con-
nective tissue [33].
Materials and methods
Animals
Female Lewis rats (10–12 weeks of age) were obtained from
the Institute of Animal Studies, Friedrich Schiller University
Jena, Germany. The rats were housed under standard condi-
tions, in a 12-hour light/dark cycle. The animals were fed with
standard rodent chow and water ad libitum. The rats were
divided into two groups: non-arthritic animals (n  = 6) and
arthritic animals (n = 40). The latter were subdivided into the
following groups (each n = 10): untreated AIA rats, short-term
test (US); untreated AIA rats, long-term test (UL); HA-treated
AIA rats, short-term test (HS); and HA-treated AIA rats, long-
term test (HL). All animal studies were approved by the gov-
ernmental committee for animal protection.
Hyaluronic acid
Pyrogen-free, sterile-filtered HA with a molecular weight of 1.7
× 106 Da was used, obtained by biotechnological fermentation
from Streptococcus equisimilis ssp. zooepidemicus V 2541.
This bacterial HA, also called non-animal-source hyaluronan, is
completely identical to human HA. The content of pyrogen was
minimised to less than 0.05 IE/ml HA by cleaning steps, there-
fore fulfilling the demands of the European Pharmacopeia
(Supplement 2001, page 1472). The zero-viscosity of the puri-
fied 1.0% high-molecular-weight HA (molecular weight, 1.7 ×
106 Da) in 0.9% NaCl solution amounted to h0 = 10.74 Pa s.
The injection units contained 10 mg HA in 1 ml of 0.9% NaCl.
Induction of AIA
All experimental animals were immunised by two subcutane-
ous injections (days -21 and -14) of 0.5 g methylated bovine
serum albumin (mBSA), dissolved in 0.5 ml saline and emulsi-
fied with 0.5 ml complete Freund's adjuvant [32,34]. Knee
monoarticular arthritis was induced 2 weeks after the second
immunisation via a single joint injection of 0.5 mg mBSA (50
µl of 10 mg/ml mBSA dissolved in 0.9% NaCl) into the right
knee joint (day 0 of AIA). The left knee remained without
injection.
Treatment with HA
On day 1 of AIA, all 40 arthritic animals received an intra-artic-
ular injection into the right inflamed knee joint. HA-treated AIA
rats (groups HS and HL) received in each case 0.5 mg HA (50
µl of 10 mg/ml HA in 0.9% NaCl), whereas the untreated AIA
rats (groups US and UL) received 50 µl PBS. The AIA rats of
the long-term test received further injections at the beginning
of each subsequent week (days 8, 15, and 22): the HL group
received 50 µl HA, and the UL group received 50 µl PBS.
The short-term test (groups US and HS) was terminated 1
week after the first injection of HA or PBS (day 8). The long-
term test (groups UL and HL) was terminated 1 week after the
fourth injection (day 29).Available online http://arthritis-research.com/content/7/3/R677
R679
In all cases, the contralateral (left) knee joint remained
untreated. The group of six non-arthritic animals without AIA
(12 weeks of age) served for the collection of normal values.
All injections (including those necessary to induce immunisa-
tion and knee AIA) were performed under ether anaesthesia.
At the end of the experiment, the animals were sacrificed using
an overdose of CO2 and cervical dislocation.
Collection of samples
Blood samples were collected by heart puncture after opening
the thorax. The blood was centrifuged for 10 min at 3000 × g
and ambient temperature. The serum was divided into three
portions of at least 250 µl and was frozen at -80°C until
analysis.
The knee joints were disconnected from the long bones and
stored in 6% formaldehyde. In order to ensure an optimal
impregnation with formaldehyde, the adhering remainders of
the long bones were kept very short (approximately 1.0 cm
above and below the joint space) and the dorsal joint capsule
was opened.
Evaluation of arthritis
Joint swelling, body weight, and the general state of the ani-
mals were regularly monitored. The measurements of weight
and mediolateral joint diameter took place on days 0, 1, 4, 8,
15, 22, and 29. The mediolateral joint diameter was measured
using a vernier caliper [32,34].
Histological analyses
All preparations were stored in 6% formaldehyde for 24 hours.
Decalcification in ethylenediamine tetraacetic acid subse-
quently took place and the preparations were embedded in
paraffin. After the removal of paraffin, 5-µm thick sections were
cut [35].
For the assessment of the histological arthritis scores, the sec-
tions were stained with haematoxylin and eosin. All slides were
evaluated by an independent observer who was blinded to the
design and details of the study. In all cases, three sections per
knee joint were examined and scored using a semiquantitative
scale.
The extent of acute joint inflammation – as defined by the
degree of infiltration of the synovial membrane by polymorpho-
nuclear leukocytes, and defined by the exudation of granulo-
cytes in the joint space – was evaluated in each case with 0 =
no changes, 1 = mild changes, 2 = moderate changes, and 3
= severe changes. In addition, the presence (score 1) or
absence (score 0) of fibrin exudation in the joint space and
periarticular inflammation was assessed, resulting in a maxi-
mum total score of 8 for acute inflammation.
Chronic joint inflammation – based on the parameters hyper-
plasia of synovial lining cells, infiltration by mononuclear cells,
and fibrosis of synovial membrane or periarticular tissue – was
evaluated with a score of 0–3, resulting in a maximum total
score of 9.
The extent of the damage to articular cartilage and adjacent
bone structures (cell necrosis, structural bone, and cartilage
defects) was evaluated with score 0 = no damage, score 1 =
<5% of the cartilage surface affected, score 2 = 5–10% of the
cartilage surface affected, score 3 = 10–50% of the cartilage
surface affected, and score 4 = >50% of the cartilage surface
affected (maximal total score of 4).
Safranin O staining was performed to estimate the proteogly-
can content in the cartilage [36-38]. In order to obtain compa-
rable histological results, all slides were stained using exactly
the same procedure [39]. The preparations were analysed
under defined conditions using a Zeiss microscope Axiovert
200 M (20 × magnification) (Carl Zeiss, Göttingen, Germany)]
and the results were stored as pixel pictures. The staining
intensity was determined in 175 × 25 mm2 areas, using Scion
Image software (Scion Corporation, Frederick, MD, USA).
First, the staining intensity (red) at the epiphyseal growth plate
of the femoral condyle of non-arthritic and arthritic animals was
measured (maximum value 255). The arithmetic mean
obtained from these values was used as a reference value
(232 [= 100%]). The measurements of articular cartilage took
place at the most distal point of the curvature of the femoral
condyle. In each case, values were obtained for the superficial
layer, middle layer, and deep layer of the hyaline cartilage, as
well as for the calcified cartilage layer (Fig. 1). Data were
expressed as a percentage of the reference value. Subse-
quently, the values of the contralateral, non-arthritic knee joint
(left) were subtracted from the arthritic knee (right), resulting
in negative values in the case of proteoglycan loss.
Cytokine and serum glycosaminoglycan evaluation
The serum levels of IL-6, tumour necrosis factor alpha (TNF-α )
and glycosaminoglycan (GAG) were determined at the end
point of the short-term test (day 8) and at the endpoint of the
long-term test (day 29).
The serum levels of IL-6 and TNF-α  were determined using a
commercial sandwich ELISA kits for rats according to the
manufacturer's instructions (Biosource International, Camal-
liro, CA, USA). The detection limits were 8 pg/ml for IL-6 and
4 pg/ml for TNF-α . According to the manufacturer, there was
no cross-reactivity with other rat cytokines.
The serum levels of total GAG were measured in non-diluted
serum with a commercially available kit. The standard values
for healthy rats were 10.8–17.4 mg/l (Glycane T Labor + Diag-
nostica, Freital, Germany).Arthritis Research & Therapy    Vol 7 No 3    Roth et al.
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Statistics
Statistical evaluations were carried out using the programme
SigmaStat 2.0. Since nearly all data were not normally distrib-
uted, the non-parametric Mann–Whitney U test was used.
Data were expressed as means and standard errors of the
means. P ≤  0.05 was considered statistically significant for α .
In cases in which P values for α  were at the limits of signifi-
cance (0.05 ≤  P ≤  0.1; joint swelling day 29, cartilage damage
day 8), the statistical power of the U test was determined
using the actual difference at a given time point as delta.
Because for the time period from day 0 to day 8 the procedure
and results did not differ between the US and UL groups or
between the HS and HL groups, respectively, the values from
the short-term test and the long-term test were pooled for sta-
tistical evaluation of this period in both cases.
Results
Body weight
At baseline, the body weight was 188 ± 29 g (untreated AIA
rats) and 197 ± 22 g (HA-treated AIA rats). After a plateau
between day 0 and day 8 in both untreated rats and HA-
treated AIA rats, the body weight rose in concomitance with
the decrease of arthritis severity. At the end of the long-term
test (day 29), the animals weighed 213 ± 15 g (untreated AIA
rats) and 230 ± 13 g (HA-treated AIA rats). The differences
between the groups did not reach statistical significance at
any time point.
Joint swelling
On day 1, AIA developed as a significant swelling of the right
knee joint in all animals (Fig. 2). The swelling increased up to
day 4 in untreated AIA rats (P < 0.001, n = 20), significantly
decreasing on day 8 (P < 0.001, n = 20). The swelling then
continued to slowly decrease until day 29 (P < 0.001, n = 10).
At all time points after initiation of AIA, the swelling remained
significantly higher compared with the baseline levels on day
0 (Fig. 2).
Intra-articular treatment with HA did not significantly affect the
degree of joint swelling on days 1, 4, and 8 (Fig. 2). On day 15
(groups UL and HL, n  = 10 each) there was a significant
reduction of joint swelling in the HA-treated AIA group com-
pared with the untreated AIA group (P < 0.05). On day 22 the
swelling was no longer significantly different from the
untreated AIA group (P = 0.37); in fact, it was even somewhat
higher. On day 29 (end of the long-term test) the small
increase of joint swelling in the HA-treated AIA group per-
sisted (as compared with the untreated AIA group), although
without reaching statistical significance (power 1 β  = 0.851).
In general, therefore, HA seemed to positively affect the early
chronic phase of AIA (day 15), but did not have an influence
on the acute or late chronic phases of AIA, at least in terms of
joint swelling.
Figure 1
Measurement frames for Safranin O staining of the knee joint cartilage Measurement frames for Safranin O staining of the knee joint cartilage. 
After elimination of green tones and transformation of all red tones into 
grey tones, the staining intensity (a measure of the proteoglycan con-
tent) was determined in the following layers: S, superficial layer; M, mid-
dle layer; D, deep layer; and C, calcified cartilage.
Figure 2
Time course of knee joint swelling Time course of knee joint swelling. Joint swelling (difference between 
the bilateral diameter of the right knee and the left knee) in untreated 
antigen-induced arthritis (AIA) rats and in hyaluronic acid (HA)-treated 
AIA rats. V, end of the short-term test (day 8) and end of the long-term 
test (day 29). The arrows indicate the days of intra-articular injection of 
HA (days 1, 8, 15, and 22). In the short-term test there was no signifi-
cant difference between HA-treated rats and untreated AIA rats. In the 
long-term test HA-treated AIA rats showed significantly reduced values 
on day 15 (* P < 0.05). On day 29 there were no longer differences 
between the two groups; if at all, the swelling in the HA-treated group 
was somewhat higher than in untreated AIA group.
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Loss of proteoglycans from the epiphyseal growth plate 
of the femoral condyle and the articular cartilage
In the short-term test (day 8), the untreated AIA group was
characterised by a significant decrease of the proteoglycan
content in the epiphyseal growth plate of the arthritic right
knee compared with the contralateral knee or with the right
knee joint of non-arthritic animals (in both cases, P < 0.05; Fig.
3). Treatment with HA prevented this loss, maintaining prote-
oglycan levels close to those of non-arthritic animals.
In terms of individual zones of the articular cartilage, the
untreated AIA rats underwent a change of -37% in the super-
ficial layer, -26% in the middle layer, -13% in the deep layer,
and -15% in the calcified cartilage layer (Figs 4b,d and 5). At
this time point, treatment with HA was significantly effective in
preventing the proteoglycan loss in the superficial layer (P <
0.01), the middle layer (P < 0.05), and the calcified cartilage
layer (P < 0.05; Figs 4b,f and 5). In all layers, the proteoglycan
content reached normal levels.
In the long-term test (day 29) there was no significant loss of
proteoglycan content in the epiphyseal growth plate of
untreated AIA rats (see Fig. 3). However, treatment with HA
was characterised by a significant proteoglycan loss in the
growth plate of the arthritic right knee compared with the con-
tralateral knee or with the right knee joint of non-arthritic ani-
mals (P < 0.001; Fig. 3).
In the different layers of the articular cartilage, the untreated
AIA rats no longer showed any significant proteoglycan loss;
that is, there were no significant differences between the right
knee joints and left knee joints of AIA rats, or between the right
knee joint of AIA rats and the right knee joint of non-arthritic
animals (Fig. 5; Safranin O staining data not shown). Treat-
ment with HA did not significantly affect the proteoglycan con-
tent in any layer of the articular cartilage.
Figure 3
Safranin O staining intensity in the epiphyseal growth plate of the femo- ral condyle Safranin O staining intensity in the epiphyseal growth plate of the femo-
ral condyle. The reference value of 232 (100%; continuous line) was 
obtained by computing all available values from both non-arthritic rats 
and antigen-induced arthritis (AIA) rats. In untreated AIA rats, the right 
(arthritic) joint showed a significant reduction of proteoglycan content 
of the epiphysis in the short-term test (day 8; *P < 0.05). This loss was 
not observed following hyaluronic acid (HA) treatment (day 8). The lat-
ter values were comparable with non-arthritic animals and with the con-
tralateral joint (data not shown). Long-term treatment with HA (day 29) 
induced a significant loss of proteoglycans in the epiphyseal growth 
plate (*** P < 0.001). In contrast, the arthritic joints of untreated AIA 
rats showed values comparable with non-arthritic rats and contralateral 
joints (not shown).
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Figure 4
Histological findings in synovial tissue and articular cartilage: Histological findings in synovial tissue and articular cartilage: haematox-
ylin and eosin (HE) staining (a, c, e, g, and h) for acute inflammation 
(arrowheads), chronic inflammation (*), and cartilage damage (arrows), 
as well as Safranin O staining (b, d, and f) for proteoglycan depletion 
(arrows). Images are shown for non-arthritic rats (a and b), untreated 
antigen-induced arthritis (AIA) rats (day 8, c and d; day 29, g), and 
hyaluronic acid hyaluronic acid (HA)-treated AIA rats (day 8, e and f; 
day 29, h). The bar indicates the distance in the histological section. 
SM, synovial membrane; P, patella; FE, femur. Safranin O staining: S, 
superficial layer; M, middle layer; D, deep layer; and C, calcified carti-
lage. N, non-arthritic rats; US, untreated AIA, short-term test; HS, HA-
treated AIA, short-term test; UL, untreated AIA, long-term test; HL, HA-
treated AIA, long-term test.Arthritis Research & Therapy    Vol 7 No 3    Roth et al.
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Histological scores of arthritis and cartilage damage
In the short-term test (day 8) there was a strong acute inflam-
mation in untreated AIA rats (Fig. 6a). Treatment with HA sig-
nificantly reduced the acute inflammation compared with the
untreated AIA group (P < 0.05; Figs 4a,c,e and 6a). Notably,
the untreated AIA group underwent a complete, spontaneous
remission of the acute inflammation score from day 8 to day 29
(acute inflammation score nearly 0 in the long-term test; Figs
4c,g and 6a). The HA-treated AIA group in the long-term test
clearly improved compared with the short-term test (P < 0.05),
but it still showed significantly higher, residual acute inflamma-
tion than the untreated AIA group (P < 0.05; Figs 4e,g,h and
6a).
In the short-term test (day 8) a clear score for chronic inflam-
mation was also observed (Figs 4a,c,e and 6b), without signif-
icant differences between untreated and HA-treated AIA
groups. The chronic inflammation significantly decreased from
day 8 to day 29 in untreated and HA-treated AIA (group US
versus group UL, P < 0.001; group HS versus group HL, P <
0.01; Figs 4c,e,g,h and 6b). Unexpectedly, however, on day
29 the chronic inflammation score was more pronounced in
Figure 5
Safranin O staining intensity in different layers of the articular cartilage Safranin O staining intensity in different layers of the articular cartilage. 
Comparisons were made for different layers (S, superficial layer; M, 
middle layer; D, deep layer; and C, calcified cartilage) between non-
arthritic rats, untreated antigen-induced arthritis (AIA) rats, and 
hyaluronic acid (HA)-treated AIA rats in terms of relative differences 
between right (arthritic) and left (contralateral) joints. In the short-term 
test (day 8) untreated AIA rats showed a reduced proteoglycan content 
in the superficial layer (** P = 0.01), middle layer (* P < 0.05), and cal-
cified cartilage (* P < 0.05). HA-treated AIA rats showed proteoglycan 
contents comparable with those of non-arthritic rats in all layers. In the 
long-term test (day 29), untreated AIA rats also showed reduced prote-
oglycan contents in all layers compared with non-arthritic rats, but no 
statistical significance was attained. HA-treated AIA rats showed prote-
oglycan contents comparable with those of non-arthritic rats.
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Figure 6
Histological scores Histological scores. In the short-term test, hyaluronic acid (HA)-treated 
antigen-induced arthritis (AIA) rats showed a significant reduction of (a) 
the acute inflammation score compared with untreated AIA rats (* P < 
0.05). The score of (b) chronic inflammation and (c) cartilage damage 
did not show significant differences between HA-treated rats and 
untreated AIA rats. In the long-term test, (a) the acute inflammation was 
reduced in both AIA groups compared with that in the short-term test 
(HA-treated AIA rats, P < 0.05; untreated AIA rats, P < 0.001; signifi-
cance not indicated); nonetheless, the HA-treated AIA rats showed sig-
nificantly higher scores than untreated AIA rats on day 29 (* P < 0.05). 
(b) The scores of chronic inflammation were reduced in both AIA 
groups compared with the short-term test (untreated AIA rats, P < 
0.001; HA-treated AIA rats, P < 0.01; significance not indicated); none-
theless, the HA-treated rats showed significantly higher scores than 
untreated AIA rats on day 29 (* P < 0.05). (c) The cartilage damage 
was relatively low in both untreated rats and HA-treated AIA rats, but 
HA-treated AIA rats showed a significantly higher damage (* P < 0.05).
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the animals treated with HA compared with the untreated AIA
group (P < 0.05; Figs 4g,h and 6b).
In terms of cartilage damage, the untreated AIA group was
characterised by a maximum individual score of 3; that is, the
maximal possible score of 4 was not observed (Fig. 6c). On
day 8, the mean cartilage damage was somewhat more pro-
nounced in the untreated AIA group, but without significant dif-
ferences in comparison with the HA-treated AIA group (power
1 - β  = 0.821). From day 8 to day 29, the cartilage damage
decreased significantly in untreated rats and HA-treated AIA
rats (group US versus group UL, P < 0.001; group HS versus
group HL, P < 0.01). In the long-term test (day 29), however,
the cartilage damage was significantly higher in the animals
treated with HA than in the untreated AIA group (P < 0.05; Fig.
6c).
Systemic cytokine levels
In non-arthritic animals, the serum IL-6 levels were below the
detection limit of the assay (Fig. 7a). Untreated AIA rats had
significantly elevated IL-6 levels both in the short-term test and
in the long-term test (P < 0.001 in both cases; significance not
indicated in Fig. 7). Treatment with HA did not significantly
influence IL-6 levels at either time point (Fig. 7a).
As for TNF-α , non-arthritic animals had mean serum levels of
5.45 ± 4.56 pg/ml (Fig. 7b). In the short-term test these values
were increased both in the untreated and in the HA-treated
AIA groups, but not to a significant degree. In the long-term
test, the mean TNF-α  levels were very similar to those of non-
arthritic animals. Treatment with HA did not significantly influ-
ence TNF-α  levels at either time point (Fig. 7b).
Serum GAG levels
In non-arthritic animals, the mean serum levels of GAG were
12.70 ± 3.30 µg/ml (Fig. 7c). Untreated AIA rats had
significantly higher GAG levels than non-arthritic animals in the
short-term test and in the long-term test (P < 0.05 and P <
0.001, respectively; significance not indicated in Fig. 7). Treat-
ment with HA had no influence on this parameter at either time
point (Fig. 7c).
Discussion
Clinical parameters of arthritis
The time course of AIA was similar to that described by other
authors [32,34], confirming that the present results were rep-
resentative of previous studies.
Treatment with HA did not reduce joint swelling in the acute
phase, as significant reduction of joint swelling was found only
on day 15 (i.e. in the early chronic phase of AIA). The tempo-
rary reduction of joint swelling may be a result of the reduced
acute inflammation observed histologically at an earlier time
point (day 8). This anti-inflammatory effect of HA is consistent
Figure 7
Serum levels of IL-6, tumour necrosis factor alpha (TNF-α ) and  glycosaminoglycan Serum levels of IL-6, tumour necrosis factor alpha (TNF-α ) and gly-
cosaminoglycan. During the course of antigen-induced arthritis (AIA), 
(a) IL-6 levels in non-arthritic rats showed values below the detection 
limit of the assay. Untreated and hyaluronic acid (HA)-treated AIA rats 
showed significantly increased values in the short-term test and in the 
long-term test compared with non-arthritic rats (all P < 0.001; data not 
shown), but HA treatment resulted in IL-6 levels comparable with those 
of untreated AIA. (b) Regarding TNF-α  levels, the only change was a 
short-term, non-significant increase in all AIA rats, whether HA-treated 
or untreated. (c) Serum values of glycosaminoglycan increased signifi-
cantly in all AIA rats compared with non-arthritic animals (non-arthritic 
animals versus untreated AIA rats [short-term test], P < 0.05, non-
arthritic animals versus HA-treated AIA rats, untreated AIA rats [long-
term test] and HA-treated AIA rats [long-term test], P < 0.001; signifi-
cance not indicated). There were no differences between short-term 
tests and long-term tests, or between HA-treated rats and untreated 
AIA rats.
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with the effects previously reported in collagen-induced arthri-
tis [22,40] and human RA [41,42].
Interestingly, however, while the joint swelling continued to
progressively and spontaneously decrease in untreated AIA, it
persisted in HA-treated animals after day 15, although the
difference remained at the limits of significance (P = 0.06).
The persistence of inflammation after prolonged application of
HA (day 29) is further substantiated by significant proteogly-
can loss in the epiphyseal growth plate, by significant persist-
ence of both acute and chronic inflammation, and by
significantly increased histological signs of articular cartilage
damage. This biphasic course regarding joint inflammation
and destruction after repeated application of high-molecular-
weight HA has not been previously described. HA therefore
probably shows only a limited temporal window of anti-inflam-
matory activity in arthritis.
Adverse reactions to HA have been described in human oste-
oarthritis, either after the first injection and subsequent intra-
articular injections or at the beginning of a new treatment
course. These adverse events consisted of pain and/or tran-
sient swelling of the injected joint, mostly mild or moderate in
intensity [43-45]. The adverse reactions observed upon intra-
articular treatment of human osteoarthritis are not comparable
with the biphasic effects in the present study, since they were
only short-lasting and limited to a period immediately following
injection.
Proteoglycans in the epiphyseal growth plate of the 
femoral condyle and the articular cartilage
AIA was accompanied by a significant loss of proteoglycans in
the epiphyseal growth plate of untreated AIA rats in the short-
term test (significantly ameliorated by HA; day 8). This prote-
oglycan loss is probably caused by the inflammatory micromi-
lieu in the arthritic joint [46] and the adjacent periarticular bone
marrow [47], in analogy to the alterations of the primary and
secondary spongiosa in AIA [48]. The significant prevention of
proteoglycan loss from the epiphyseal growth plate by HA at
this time point may be due to the clear anti-arthritic effects of
HA, as also documented by the significant decrease of acute
inflammation on day 8 (Fig. 6a). Whether intra-articular treat-
ment with HA indirectly influences the inflammatory changes in
the bone marrow, thereby preventing proteoglycan loss in the
epiphyseal growth plate, remains to be investigated.
Unexpectedly, repeated intra-articular HA treatment induced
proteoglycan loss in the epiphyseal growth plate in the long-
term test (day 29). This late loss of proteoglycans in the epiph-
ysis under prolonged HA treatment suggests late
proinflammatory effects of HA, as also indicated by signifi-
cantly elevated levels of acute and chronic inflammation, as
well as cartilage damage (Fig. 6).
Regarding the proteoglycan content within the articular carti-
lage, HA completely prevented the proteoglycan loss in the
short-term test. This applied to the severe loss of proteogly-
cans in the superficial layer — the layer most strongly affected
in the present study (37%) and also that most strongly
affected in the fibronectin-mediated arthritis model [19]. This
prevention also applied to deeper layers of the calcified carti-
lage, however, indicating either deep-reaching effects of intra-
articular HA (up to 100 µm; see Fig. 1) or an indirect effect on
the micromilieu in the epiphyseal bone core. Such profound
chondroprotective effects of HA have not previously been
reported in an in vivo arthritis model. Previous in vitro studies,
in which the proteoglycan release from the cell matrix of bovine
chondrocyte cultures was inhibited by HA, have suggested a
covering of the matrix of as a mechanism for the chondropro-
tective capacity of HA [19].
Acute and chronic inflammation, and cartilage damage
HA reduced the histological signs of acute inflammation in the
short-term test (day 8). At this point, HA also showed a ten-
dency (P = 0.06) to protect the joint again against cartilage
damage (Fig. 6c). The tendency for decreased cartilage dam-
age in the short-term test supports the assumption that HA
forms a temporary protecting barrier over the cartilage, and
thereby protects it against degradation [16,19,49]. The known
reduction of free oxygen radicals [31], as well as the reduction
of cytokines and other mediators of acute inflammation by HA
[15,21], could contribute to both its chondroprotective capac-
ity (Fig. 6c) and its anti-inflammatory effects (Fig. 6a) in early
chronic AIA (day 8).
In the long-term test (day 29) HA treatment was associated
with significantly higher histological signs of acute and chronic
inflammation and, more importantly, with more severe cartilage
damage. The late proinflammatory effects of repeated HA
application, in parallel to the late loss of epiphysis proteogly-
cans and late damage of articular cartilage (see earlier), point
to an interdependence of inflammation and damage in HA-
treated AIA rats at this stage.
Significantly higher histological signs of articular cartilage
damage after repeated HA application (day 29) are in contrast
to a non-altered proteoglycan content of the articular cartilage
at this time (Fig. 5). A seemingly normal proteoglycan content
may therefore not be sufficient to exclude structural damage of
the articular cartilage in arthritis. Consequently, more sensitive
in vivo procedures will have to be established to reliably
assess functional or structural cartilage alterations before irre-
versible damage occurs [50].
Serum levels of cytokines and GAG
In the present study, the systemic levels of IL-6, TNF-α  and
GAG were not significantly influenced by intra-articular admin-
istration of high-molecular-weight HA, indicating that both anti-Available online http://arthritis-research.com/content/7/3/R677
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inflammatory effects (day 8) and proinflammatory effects (day
29) are locally restricted.
Conclusion
In conclusion, HA appears to have a limited therapeutic win-
dow for local treatment of arthritis, as shown by amelioration
of clinical signs (day 15), by prevention of proteoglycan loss in
the articular cartilage and epiphyseal growth plate, and by
prevention of structural cartilage damage, as well as by the
reduction of acute inflammation in the arthritic joint (day 8).
Late aggravation of clinical signs (not significant, day 29), pro-
teoglycan loss from the epiphyseal growth plate, and acute/
chronic inflammation and structural cartilage damage at this
time point strongly indicate biphasic effects of local HA
treatment.
Whether these biphasic effects are due to accumulation of HA
beyond pathological levels (which may be avoidable by single
injection instead of repeated injection) or whether certain
phases of the clinical course render the animals sensitive to
the proinflammatory effects of HA remains the subject of future
research, both in animal models and in human RA.
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